Autophagy, mitochondrial quality control, and oncogenesis

Autophagy

Volumn 2, Issue 2, 2006, Pages 80-84

  Jin, Shengkan ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Aging; Autophagy; Mitochondria; ROS; Tumor suppression

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; DNA; HYDROGEN PEROXIDE; PROTEIN BECLIN 1; REACTIVE OXYGEN METABOLITE; SUCCINATE DEHYDROGENASE; SUPEROXIDE DISMUTASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AGING; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME 17Q; ENZYME DEGRADATION; EUKARYOTIC CELL; GENE DELETION; HUMAN; LIPOGENESIS; MITOCHONDRION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; QUALITY CONTROL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EUKARYOTA;

EID: 33645905712     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.2.2.2460     Document Type: Review

References (53)

1. Hanahan D, Weinberg RA The hallmarks of cancer. Cell 2000; 100:57-70.
2. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999; 402:672-6.
3. Qu X, Yu J, Bhagat B, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, Cattoretti G, Levine B. Promotion of tumorigenesis by hetetozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003; 112:1809-20.
4. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 2003; 100:15077-82.
5. Melendez A, Talloczy Z, Seaman M, Eskelinen EL, Hall DH, Levine B. Autophagy genes are essential for dauer development and life-span extension in C. elegans. Science 2003; 301:1387-91.
6. Liang XH, Kleeman LK, Jiang HH, Gordon G, Goldman JE, Berry G, Herman B, Levine B. Protection against fatal Sindbis virus encephalitis by Beclin, a novel Bcl-2-interacting protein. J Virol 1998; 72:8586-96.
7. Aita VM, Liang XH, Murty VWS, Pincus DL, Yu W, Cayanis E, Kalachikov S, Gilliam TC, Levine B. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q2l. Genomics 1999; 59:59-65.
8. Ohsumi Y. Molecular mechanism of autophagy in yeast, Saccharomyces cerevisiae. Philos Trans R Soc Lond B Biol Sci 1999; 354:1577-81.
9. Tsukada M, Ohsumi Y. Isolation and characterization of autophagy-defective mutants of Saccharomyccs cerevisiac. FEBS Lett 1993; 333:169-74.
10. Balsara BR, Pei J, De Rienzo A, Simon D, Tosolini A, Lu YY, Shen FM, Fan X, Lin WY, Buetow KH, London WT, Testa JR. Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes Cancer 2001; 30:245-53.
11. Bando K, Nagai H, Matsumoto S, Koyama M, Kawamura N, Tajiri T, Onda M, Emi M. Identification of a 1-Mb common region at 16q24.1-24.2 deleted in hepatocellular carcinoma. Genes Chromosomes Cancer 2000; 28:38-44.
12. Chen T, Sahin A, Aldaz CM. Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: Refining a putative tumor suppressor gene region. Cancer Res 1996; 56:5605-9.
13. Cleton-Jansen AM, Callen DF, Seshadri R, Goldup S, McCallum B, Crawford J, Powell JA, Settasatian C, van Beerendonk H, Moerland EW, Smit VT, Harris WH, Millis R, Morgan NV, Barnes D, Mathew CG, Cornelisse CJ. Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. Cancer Res 2001; 61:1171-7.
14. Elo JP, Harkonen P, Kyllonen AP, Lukkarinen O, Poutanen M, Vihko R, Vihko P. Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res 1997; 57:3356-9.
15. Launonen V, Mannermaa A, Stenback F, Kosma VM, Puistola U, Huusko P, Anttila M, Bloigu R, Saarikoski S, Kauppila A, Winqvist R. Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: Correlation to clinicopathological variables. Cancer Genet Cytogenet 2000; 122:49-54.
16. Suzuki S, Moore DH, Ginzinger DG, Godfrey TE, Barclay J, Powell B, Pinkel D, Zaloudek C, Lu K, Mills G, Berchuck A, Gray JW. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 2000; 60:5382-5.
17. Miyakis S, Liloglou T, Kearney S, Xinarianos G, Spandidos DA, Field JK. Absence of mutations in the VHL gene but frequent loss of heterozygosity at 3p25-26 in nonsmall cell lung carcinomas. Lung Cancer 2003; 39:273-7.
18. Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, Ezaki J, Mizushima N, Ohsumi Y, Uchiyama Y, Kominami E, Tanaka K, Chiba T. Impairment of starvation-induced and constitutive autophagy in Atg-7-deficient mice. J Cell Biol 2005; 169:425-34.
19. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 2005; 102:8204-9.
20. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Pue J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-7.
21. van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277:805-8.
22. European Chromosome 16 Tuberous Sclerosis Consortium, T. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993; 75:1305-15.
23. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Nad Acad Sci USA 2001; 98:10983-5.
24. Lawlor MA, Alessi DR. PKB/Akt: A key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001; 114:2903-10.
25. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96:4240-5.
26. Finch CE, Ruvkun G. The genetics of aging. Annu Rev Genomics Hum Genet 2001; 2:435-62.
27. Clancy DJ, Gems D, Harshman LG, Oldham S, Stocker H, Hafen E, Leevers SJ, Partridge L. Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science 2001; 292:104-6.
28. Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, Cervera P, Le Bouc Y. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 2003; 421:182-7.
29. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxídants, and aging. Cell 2005; 120:483-95.
30. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu Rev Genet 2005; 39:359-407.
31. Harman D. Aging: A theory based on free radical and radiation chemistry. J Gerontol 1956; 11:298-300.
32. Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, Jen J, Sidransky D. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000; 287:2017-9.
33. Penta JS, Johnson FM, Wachsman JT, Copeland WC. Mitochondrial DNA in human malignancy. Mutat Res 2001; 488:119-33.
34. Tan DJ, Bai RK, Wong LJ. Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Res 2002; 62:972-6.
35. Bianchi NO, Bianchi MS, Richard SM. Mitochondrial genome instability in human cancers. Mutat Res 2001; 488:9-23.
36. Richard SM, Bailliet G, Paez GL, Bianchi MS, Peltomaki P, Bianchi NO. Nuclear and mitochondrial genome instability in human breast cancer. Cancer Res 2000; 60:4231-7.
37. Parrella P, Xiao Y, Fliss M, Sanchez-Cespedes M, Mazzarelli P, Rinaldi M, Nicol T, Gabrielson E, Cuomo C, Cohen D, Pandit S, Spencer M, Rabitti C, Fazio VM, Sidransky D. Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res 2001; 61:7623-6.
38. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000; 26:268-70.
39. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myets EN, Richard IIIrd CW, Cornelisse CJ, Devilee P, Devlin B. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287:848-51.
40. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30:406-10.
41. Van Remmen H, Ikeno Y, Hamilton M, Pahlavani M, Wolf N, Thorpe SR, Alderson NL, Baynes JW, Epstein CJ, Huang TT, Nelson J, Strong R, Richardson A. Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiol Genomics 2003; 16:29-37.
42. Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev 1998; 78:547-81.
43. Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, Bohlooly YM, Gidlof S, Oldfors A, Wibom R, Tornell J, Jacobs HT, Larsson NG. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004; 429:417-23.
44. Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE, Hofer T, Seo AY, Sullivan R, Jobling WA, Morrow JD, Van Remmen H, Sedivy JM, Yamasoba T, Tanokura M, Weindruch R, Leeuwenburgh C, Prolla TA. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005; 309:481-4.
45. 3H-thymidine-injected rats. Cell Tissue Res 1976; 172:149-56.
46. Jazayeri M, Andreyev A, Will Y, Ward M, Anderson CM, Clevenger W. Inducible expression of a dominant negative DNA polymerase γ depletes mitochondrial DNA and produces a p° phenotype. J Biol Chem 2003; 278:9823-30.
47. Ezaki J, Tanida I, Kanehagi N, Kominami E. A lysosomal proteinase, the late infantile neuronal ceroid lipofuscinosis gene (CLN2) product, is essential for degradation of a hydrophobic protein, the subunit c of ATP synthase. J Neurochem 1999; 72:2573-82.
48. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000; 290:1717-21.
49. Kissova I, Deffieu M, Manon S, Camougrand N. Uth1p is involved in the autophagic degradation of mitochondria. J Biol Chem 2004; 279:39068-74.
50. Priault M, Salin B, Schaeffer J, Vallette FM, di Rago JP, Martinou JC. Impairing the bioenergetic status and the biogenesis of mitochondria triggers mitophagy in yeast. Cell Death Differ 200; 12:1613-21.
51. Lemasters JJ. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res 2005; 8:3-5.
52. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, Nishimura Y, Crowe RA, Cascio WE, Bradham CA, Brenner DA, Herman B. The mitochondrial permeability transition in cell death: A common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1998; 1366:177-96.
53. Cancer Facts and Figures 2002. Atlanta, GA: American Cancer Society, Inc.